Caspofungin + Amphotericin B Deoxycholate
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Candidiasis, Invasive
Conditions
Candidiasis, Invasive
Trial Timeline
Jan 15, 2014 → Feb 28, 2018
NCT ID
NCT01945281About Caspofungin + Amphotericin B Deoxycholate
Caspofungin + Amphotericin B Deoxycholate is a phase 2 stage product being developed by Merck for Candidiasis, Invasive. The current trial status is terminated. This product is registered under clinical trial identifier NCT01945281. Target conditions include Candidiasis, Invasive.
What happened to similar drugs?
5 of 20 similar drugs in Candidiasis, Invasive were approved
Approved (5) Terminated (4) Active (12)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01945281 | Phase 2 | Terminated |
Competing Products
20 competing products in Candidiasis, Invasive
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 29 |
| Isavuconazole + Caspofungin + Voriconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin + fluconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin (Mycamine) | Astellas Pharma | Phase 1 | 29 |
| Fluconazole + Micafungin | Astellas Pharma | Approved | 35 |
| Micafungin + Caspofungin | Astellas Pharma | Phase 3 | 40 |
| Micafungin + Fluconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin | Astellas Pharma | Phase 2 | 35 |
| micafungin + caspofungin | Astellas Pharma | Phase 3 | 40 |
| micafungin + amphotericin B deoxycholate | Astellas Pharma | Phase 3 | 32 |
| FK463 | Astellas Pharma | Phase 2 | 35 |
| Micafungin + Liposomal Amphotericin B | Astellas Pharma | Phase 3 | 40 |
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| L-743,872 | Merck | Pre-clinical | 26 |
| Caspofungin | Merck | Phase 2 | 35 |
| L-743,872 | Merck | Phase 2 | 27 |
| Caspofungin acetate + Placebo | Merck | Phase 2 | 27 |
| Caspofungin + Normal Saline | Merck | Approved | 43 |
| caspofungin acetate | Merck | Phase 3 | 40 |